GlaxoSmithKline Pharmaceuticals Limited (GSK India) has announced its financial results for the quarter ended June 30, 2025. The company reported consistent profitability while continuing to invest in key product areas to support long-term growth.
Revenue from operations for the quarter stood at ₹805 crore, and profit after tax reached ₹205 crore. While overall growth was flat, the company remains focused on its core therapeutic segments, including anti-infectives, pain relief, and skin health.
GSK India’s general medicines portfolio delivered a solid performance in a competitive market, with several promoted brands gaining share and outpacing market trends, according to IQVIA data. However, the overall outcome fell short of expectations, mainly due to external challenges such as seasonal disruptions that affected demand patterns.
In the vaccines division, the company continued to strengthen its leadership position in the self-funded private pediatric market. Its adult vaccines segment is gaining traction as well, with rising demand for Shingrix, a vaccine for shingles (herpes zoster), supporting GSK’s broader push to improve adult immunization in India.
The company also highlighted ongoing efforts to introduce medical innovations aimed at delivering advanced care for Indian patients. A major development on the horizon is the launch of its cancer treatment portfolio.
GSK is gearing up to expand its oncology portfolio with the launch of two cancer treatments aimed at addressing critical unmet needs. The first, Jemperli (dostarlimab), is an immunotherapy designed to treat specific forms of endometrial cancer. It works by helping the body’s immune system recognize and attack cancer cells, offering a promising option for patients with limited treatment alternatives.
The second therapy, Zejula (niraparib), is targeted at advanced or recurrent ovarian cancer. As a PARP inhibitor, it interferes with cancer cell DNA repair mechanisms, thereby slowing disease progression. Both therapies reflect GSK’s commitment to strengthening its position in oncology by delivering innovative and personalized treatment options.
“These launches mark a significant step in providing access to advanced oncology treatments in India, where the need for such therapies is growing rapidly,” said Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited. “We are committed to addressing gaps in care and supporting patients with better treatment options.”
GlaxoSmithKline Pharmaceuticals (GSK) is a leading global healthcare company, renowned for its diverse portfolio of pharmaceutical products, vaccines, and consumer healthcare goods. Operating across more than 100 countries, GSK focuses on improving the quality of human life by enabling people to do more, feel better, and live longer. The company’s pharmaceutical division is highly regarded for its research-driven approach, particularly in areas such as respiratory, immuno-inflammation, oncology, and infectious diseases.
